Cervarix is a non-infectious recombinant, AS04-adjuvanted vaccine, that contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types 16 and 18.
Cervarix is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: • cervical cancer, • cervical intraepithelial neoplasia (CIN) Grade 2 or worse and adenocarcinoma in situ, and • cervical intraepithelial neoplasia (CIN) Grade 1.
Cervarix is approved for use in females 9 through 25 years of age
Cervarix is administered in three doses (0.5-mL each) by intramuscular injection according to the following schedule: 0, 1, and 6 months.
Cervarix was initially approved for use in the US in 2009.
October 2016: GlaxoSmithKline (GSK) announced they will no longer market its human papillomavirus (HPV) bivalent vaccine, Cervarix, in the United States.